BioSpace News Archive

Pocket Naloxone Corp. announced results from a human factors validation study, using the intend-to-market packaging and labeling, demonstrated that laypersons of varied ages and reading comprehension levels and HCPs (healthcare professionals) were successfully able to administer its novel naloxone nasal swab NaxSwab™ in a simulated emergency rescue environment to potentially revive someone from an opioid overdose.

Nucleix will premiere data from its early lung cancer detection discovery platform, the Nucleix EpiCheck® Lung Atlas, at the American Association for Cancer Research (AACR) Annual Event in Orlando, April 14-19.

Using a new approach for studying live embryonic mouse brains at single-cell resolution, researchers have identified an active multi-layer circuit that forms in the cortex during an unexpectedly early stage of development.

PUR Biologics, a wholly owned subsidiary of HippoFi, Inc. (OTC PINK:ORHB), is pleased to announce the release of PURfiberXP™, a uniquely processed demineralized extracellular matrix (d-ECM) designed to support bone regeneration, cellular integration, and patient healing.

The FDA has also recently granted an orphan drug designation (ODD) to GIVI-MPC.

Caris Life Sciences®(Caris) and Flare Therapeutics today announced a multi-year strategic collaboration to accelerate precision medicine approaches across five of Flare’s therapeutic programs into clinical trials through advanced molecular profiling approaches that guide patient selection and participation.

Ardelyx, Inc. announced that on April 10, 2023, the compensation committee of the company’s board of directors granted three new non-executive employees options to purchase an aggregate of 238,426 shares of the company’s common stock, and granted four new non-executive employees an aggregate of 89,250 Restricted Stock Units.

IGM Biosciences, Inc. announced the presentation of six posters at the upcoming American Association for Cancer Research Annual Meeting 2023, taking place in Orlando, Florida on April 14-19, 2023.

Sight Sciences, Inc., an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, announced it will host a Surgical Glaucoma Investor Symposium in San Diego, CA on Friday, May 5, 2023 at 6:00 pm PT.

Merck announced the U.S. FDA has accepted for review a new supplemental Biologics License Application seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.